[PDF][PDF] Direct‐acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local‐regional therapy or liver transplant waitlist dropout
AC Huang, N Mehta, JL Dodge, FY Yao… - Hepatology, 2018 - Wiley Online Library
Whether direct‐acting antivirals (DAAs) increase the risk of hepatocellular carcinoma (HCC)
recurrence after tumor‐directed therapy is controversial. We sought to determine the impact …
recurrence after tumor‐directed therapy is controversial. We sought to determine the impact …
Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
AC Huang, N Mehta, JL Dodge, FY Yao, NA Terrault - 2018 - cabidigitallibrary.org
Whether direct-acting antivirals (DAAs) increase the risk of hepatocellular carcinoma (HCC)
recurrence after tumor-directed therapy is controversial. We sought to determine the impact …
recurrence after tumor-directed therapy is controversial. We sought to determine the impact …
Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
AC Huang, N Mehta, JL Dodge, FY Yao… - Hepatology (Baltimore …, 2018 - europepmc.org
Whether direct-acting antivirals (DAA) increase the risk of hepatocellular carcinoma (HCC)
recurrence after tumor-directed therapy is controversial. We sought to determine the impact …
recurrence after tumor-directed therapy is controversial. We sought to determine the impact …
Direct‐acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local‐regional therapy or liver transplant waitlist dropout
AC Huang, N Mehta, JL Dodge, FY Yao, NA Terrault - Hepatology, 2018 - journals.lww.com
Whether direct‐acting antivirals (DAAs) increase the risk of hepatocellular carcinoma (HCC)
recurrence after tumor‐directed therapy is controversial. We sought to determine the impact …
recurrence after tumor‐directed therapy is controversial. We sought to determine the impact …
Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
AC Huang, N Mehta, JL Dodge, FY Yao… - Hepatology (Baltimore …, 2018 - escholarship.org
Whether direct-acting antivirals (DAAs) increase the risk of hepatocellular carcinoma (HCC)
recurrence after tumor-directed therapy is controversial. We sought to determine the impact …
recurrence after tumor-directed therapy is controversial. We sought to determine the impact …
[HTML][HTML] Direct-acting Antivirals Do Not Increase the Risk of Hepatocellular Carcinoma Recurrence after Local-Regional Therapy or Liver Transplant Waitlist Dropout
AC Huang, N Mehta, JL Dodge, FY Yao… - Hepatology (Baltimore …, 2018 - ncbi.nlm.nih.gov
Whether direct-acting antivirals (DAA) increase the risk of hepatocellular carcinoma (HCC)
recurrence after tumor-directed therapy is controversial. We sought to determine the impact …
recurrence after tumor-directed therapy is controversial. We sought to determine the impact …
Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout
AC Huang, N Mehta, JL Dodge… - Hepatology …, 2018 - pubmed.ncbi.nlm.nih.gov
Whether direct-acting antivirals (DAAs) increase the risk of hepatocellular carcinoma (HCC)
recurrence after tumor-directed therapy is controversial. We sought to determine the impact …
recurrence after tumor-directed therapy is controversial. We sought to determine the impact …
Direct‐acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local‐regional therapy or liver transplant waitlist dropout
AC Huang, N Mehta, JL Dodge, FY Yao, NA Terrault - Hepatology, 2018 - cir.nii.ac.jp
抄録< jats: p> Whether direct‐acting antivirals (DAAs) increase the risk of hepatocellular
carcinoma (HCC) recurrence after tumor‐directed therapy is controversial. We sought to …
carcinoma (HCC) recurrence after tumor‐directed therapy is controversial. We sought to …